1. Corporate Presentation
A Revolution in Mind
Corporate Presentation
July 2014
CSNX: HSM

2. www.heliusmedical.com | CSNX: HSM
Disclaimer
This presentation contains certain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from Helius Medical Technologies expectations and projections. The Ontario Securities Commission has neither approved nor disapproved the information contained in this presentation. Except for statements of historical fact relating to the Company, certain information contained herein constitutes "forward-looking statements". Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. These factors include the inherent risks involved in the development of medical devices and FDA or other international regulatory agencies, product obsolescence, the uncertainties involved in patent defense and complexities and timelines associated with medical device product approvals in multiple jurisdictions. The possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. Circumstances or management's estimates or opinions could change. The reader is cautioned not to place undue reliance on forward-looking statements.
| CSNX: HSM 1

3. www.heliusmedical.com | CSNX: HSM
Overview
Helius Medical Technologies Inc. is a medical device holding company, enabling technologies with the potential to heal us. The company is targeting vastly underserved markets with a ground breaking device to significantly enhance the body’s ability to heal itself.
The company’s initial asset is The PoNS™ Device
PoNS treats Neurological Symptoms caused by disease or trauma
The PoNS™ Device has numerous potential medical indications; tested for MS, Stroke, Tinnitus...
Existing TBI treatments largely ineffective: > 35 years since new treatments
Sizeable scope for treatment; ~660k US military TBI sufferers, 5.3M living with TBI related disability.
US armed forces committed ~$30+M (non-dilutive) to advance to FDA approval
Testing and studies, to date, provide encouraging indications
Potential FDA approval anticipated by Q3, 2016
| CSNX: HSM 2

4. Capital Structure & Financial Information
Shares
Shares outstanding
60,540,083
Options -
Warrants from financing
7,620,000
Broker Warrants from Financing
914,400
Convertible debenture
2,564,705
Fully Diluted
71,639,188
Ownership*
# Shares
Management
33,000,000
* all approximations above
Financial Overview:
$7.2 million investment ($3M from NIH, $4.1 private non dilutive donations)
$6.9 million from concurrent financing with new listing
$7.0 million Total in treasury post listing on CSE
Non Dilutive Commitment: US Army
$18.5M est. for development of registration trial and regulatory submission.
$20.0M est. for development of further indications (Tinnitus, PTSD, Sleep Improvement, Pain Management)
| CSNX: HSM 3

5. Cranial Nerve Non-Invasive Neuromodulation
The PoNS™ Device
Next Generation Device (Jun 2014)
PPAE guidance:
This is a stacked Column chart showing Army, DHP & Other funding in $M
Other: is funds POM’d by others
RAD2 Chart version from “RAD2 Program Plan Supporting Spreadsheet_bjw_rwp 25June12”.
“Amplifying the body’s ability to heal itself”
| CSNX: HSM 5

6. Important Core Concept - Neuroplasticity
Neuroplasticity describes the ability of the brain to remain “plastic”
The PoNS Device provides stimulation to the brain-stem and other brain structures via the cranial nerves
This stimulation when combined with a “task” (physical, cognitive or mental exercises)
seems to amplifies the brains self recovery
mechanism
reinforces new learning
“re-engage” existing neural networks.
Multiple disease symptoms appear to be improved.
PPAE guidance:
This is a stacked Column chart showing Army, DHP & Other funding in $M
Other: is funds POM’d by others
RAD2 Chart version from “RAD2 Program Plan Supporting Spreadsheet_bjw_rwp 25June12”.
| CSNX: HSM 6

7. www.heliusmedical.com | CSNX: HSM
PoNS 4.0 Device
| CSNX: HSM 7

8. www.heliusmedical.com | CSNX: HSM
MS Example: A Spectrum of Symptoms Multiple Sclerosis Impact Scale (MSIS-29)
Anxiety
Sleep
Wellbeing
Bladder/Bowel Control
Spasms in Limbs
Tremors
Using Hands
Stiffness
Clumsiness
Balance
Concentration
Limits on Work
Slowness
Self Transport
Clinically Significant
Psycho-Social
Physical
Physical Tasks
Impatience
Depending on Others
Mental Fatigue
Limits on Mobility
Heavy Limbs
Uncoordinated
Confidence
Moving Indoors
Grip
Carry Things
Limits on Socializing
Spontaneity
Worry about MS
Severity of Symptoms
Not at All
Extreme
One measure is a standard SELF-survey capturing 20 physical and 9 psychological measures of the impact of MS on daily living.
Notice impact on symptoms common in multiple neurological disorders:
MS, PD, TBI, Stroke, perhaps even cognitive and psycho-social disorders
| CSNX: HSM 8 8 8

9. Example Data: 20 Patient Multiple Sclerosis Pilot Study
Weeks
DGI change
* p < 0.05
** p < 0.01
*** p < 0.005
Study entry
2 wks lab
4 wks home
8 wks home
12 wks home
Two groups (10 each):
“Active” PoNS + exercises
“Control” PoNS + exercises
“Control” PoNS = no electrical stimulus
So I won’t bore you with too many details, so I’ll just show the gait results, which is more than enough.
Highlight:
DGI vs study entry
Mean results +/- 1 SE
Both groups improve  exercises effective
Active group improves more  tongue stimulation helps
Statistical significance *
Clinical significance
Clinically significant
Mean DGI
10 Active
10 Control
| CSNX: HSM 9

10. Example Data : TBI – 4 Patient Pilot study
▲=5.0 Clinically Significant Change
SOT Points
Four female subjects, mean 48.3 y/0
Moderate, close-head non-penetrating, concussive TBI
9-11 Glasgow Coma Scale
SENSORY ORGANIZATION TEST (SOT)
| CSNX: HSM 10

11. First Indication: Concussive Traumatic Brain Injury (TBI)
Military
US: – 100,000+ cases
28% of patients at Walter-Reed >$100,000,000/year
Explosive blast injury, Overpressure, Penetrating injury, Diffuse axonal injury
5.3M living with TBI related disability
1.750 TBI/ year 30% chronic disability
600,000
Retired Soldiers TBI
60,000
Active Duty Soldiers TBI
$76.5B
Cost to US
30%
Chronic Disability
Civilian
PPAE guidance:
This is a stacked Column chart showing Army, DHP & Other funding in $M
Other: is funds POM’d by others
RAD2 Chart version from “RAD2 Program Plan Supporting Spreadsheet_bjw_rwp 25June12”.
Blunt trauma
MVAs
Sports
Assaults
| CSNX: HSM 11

12. Existing TBI Treatment Largely Ineffective
“Treatment plan” involves rehabilitation efforts to teach patients how to cope with their specific injury-related symptoms.
Non-responsive TBI patients have no treatment protocol
All single therapy development has failed in multicenter clinical trials
In last 35 years no new treatment for TBI have been suggested or brought forward.
This is an underserved market with high morbidity associated cost burden….a fact well appreciated by the US Army.
| CSNX: HSM 12

13. US Army Sponsored Registration Plan
Seeking a de-novo clearance from the FDA for the treatment of Balance disorder related to mild to moderate TBI…..study primary endpoint is improvement in balance.
Confirmed as Class II, non-significant risk, device.
Collaborative Research and Development Agreement (CRADA) with the US Armed Forces
Armed forces will be providing the facilities and personnel to perform the registrational clinical trials in Balance Disorder
Providing regulatory expertise and access to special regulatory relationship with the FDA
Committed to funding additional clinical trials estimated commitment in money and services $30M+
Research collaboration agreement signed 1/22/2013
| CSNX: HSM 13

14. Milestones and use of Proceeds
First commercial PoNS (4.0) device design and manufacturing with Ximedica
Complete Phase 1B by Q2 calendar 2014
Complete Phase 2 by Q3, calendar 2014
Complete Phase 3-5 by December 31, 2014
Clinical Trial for FDA approval in TBI
Interim data from UW pilot November 2014 will instruct registration trial design
Registration clinical trial by January 30, 2015
Complete trial Q1, 2016
Submit FDA filing Q2, 2016
Obtain approval Q3, 2016
| CSNX: HSM 14

15. Milestones and use of Proceeds (cont.)
Retained Proskauer IP Firm to expand IP development
The PoNSTM device intellectual property is the subject of U.S. Patent Application 12/348,301 and Provisional Patent Application 61/019,061; 61/020,265
Maximize claims in US though collaborative relationship with USPTO
Use combination of medical method and PoNS to generate new IP
Generate Army Deployment Plan
Ensure VA system PT infrastructure is created for maximum deployment efficiency
Create Physical Therapy Support Network
Develop partnership with national suppliers by June 2015
Develop certification plan for PTCs by May 2015
Develop home base compliance monitoring structure ready to deploy Q2, 2016
Obtain CPT reimbursement code for device reimbursement Q1, 2017
Develop International Regulatory Submission Package (Q1, 2015)
Drive submission to Health Canada on a parallel track to the US submission
| CSNX: HSM 15

16. Potential Indications for PoNS Therapy
Direct Evidence
Preliminary Data
Theoretical basis
| CSNX: HSM 17

17. Market Opportunity
# of existing Patients
New Patients/ year
Multiple Sclerosis
1,800,000
10,000
TBI (Sports concussive injury)
5,300,000
1,750 million, 550,000 with Chronic disability
Parkinson’s
750,000
60,000
Stroke
7,000,000
795,000
Alzheimer’s Disease
5,400,000
1,200,000
Depression
21,000,000
11,000,000
PTSD
15,400,000
8,225,000
ADHD
5,752,000
2,600,000
Chronic Pain
100,000,000
5,000,000
PoNS device + physical or other therapy potentially treats the symptoms of multiple brain disorders/trauma
Each Indication requires clinical trial (16 months and $2M of funding)
| CSNX: HSM 18

18. Appendix

19. Competitive Landscape
NHC
NeuroSigma
Cyberonics and Others
Cefaly
Annual Sales
None
$243M
Just approved FDA
Type of Device
Non Invasive
Non Invasive and Minimally Invasive
Invasive: Implantable
Forehead Cutaneous stim.
Approved Indications
Drug Resistant Epilepsy
Migraine Headache
Units Sold
65,000 --
Anticipated Indications
TBI, MS, Parkinson and Stroke
Drug resistant Epilepsy, Post Traumatic Stress Disorder, Obesity, Cachexia
Targeted Nerve
Trigeminal
Vagus
Product Name
PoNS
Monarch ?
Product Classification
TBD
Class III
Class II
FDA Cleared No
Yes
| CSNX: HSM 20

20. US Medical Technology M&A under $750M
| CSNX: HSM 21

21. www.heliusmedical.com | CSNX: HSM
THE TEAM
Philippe Deschamps, President, Chief Executive Officer and Director
Phil Deschamps offers extensive experience in pharmaceutical and Healthcare commercialization. The depth of his expertise stems from his 28 years in the Health Sciences industry half of which was spent at Bristol Myers Squibb and half on the service side as CEO GSW Worldwide, a leading healthcare commercialization company. In February 2012 he joined MediMedia Health, a marketing services company as CEO. In October 2013 became CEO of Helius Medical Technologies.
Deschamps oversaw MediMedia Health Marketing Services business. He was responsible for the strategic development of the organization, nurturing their clients and developing new non personal Communication products and services for the Healthcare industry
At GSW, Deschamps was President and CEO and was responsible for the GSW Worldwide operations which includes offices in the 15 major markets around the world with a turnover of $160M. He primarily consulted on global marketing and commercialization, new business model development for pharmaceutical, device and diagnostics companies.
Before joining GSW Worldwide Deschamps served as director of neuroscience marketing at Bristol- Myers Squibb (BMS) in Princeton, N.J., where he participated on several pre-launch Global Marketing teams in the neuroscience and pain therapeutic areas. He also held several marketing positions in the neuroscience, pain and metabolic therapeutic areas throughout his career.
Deschamps has a BSc. From the University of Ottawa in Canada.
| CSNX: HSM 22

22. www.heliusmedical.com | CSNX: HSM
THE TEAM
Jonathan Sackier, Chief Medical Officer
Jonathan Sackier has over 30 years of healthcare experience. Trained in Britain as a surgeon & recruited to the USA in 1989 he helped lead the laparoscopic surgery revolution. As a Professor at George Washington University in Washington, DC, he founded, and funded the Washington Institute of Surgical Endoscopy, a center for education, research, innovation and technology transfer.
He is Visiting Professor of Surgery and Medicine at the University of Virginia where he teaches pro bono and his activities in basic and clinical research funded by multiple grants have led to many publications, chapters and books. He has served multiple journals in editorial or reviewer functions, been involved in medical societies at the highest level and been honored for his work in many countries.
| CSNX: HSM 25

23. www.heliusmedical.com | CSNX: HSM
THE TEAM
Kurt Kaczmarek, Mitch Tyler, Yuri Danilov
Board Directors, Inventors of PoNS Technology
Drs Kaczmarek, Tyler and Danilov founded in 1992, the Tactile Communication & Neurorehabilitation Laboratory (TCNL). It is located at the University of Wisconsin-Madison. TCNL is a research center that uses the experience of many different areas of science to study the theory and application of applied neuroplasticity, the brain’s ability to reorganize in response to new information, needs, and pathways. Their research is aimed at developing solutions for sensory and motor disorders. The center has three core areas that form the backbone of their research:  neuromodulation, sensory substitution, and electrotactile stimulation.
They are committed to enhancing the rehabilitation process. They envision a future with a faster and more complete rehabilitation from sensory and motor disorders. They strive to improve existing therapies and develop new ones for conditions, which, in the past, had few or no options. Based on the work of our founder Paul Bach-y-Rita, M.D., the originator of the line of our current research, we believe that neuroplasticity is at the heart of all successful neurorehabilitation.
The PoNS device is a result of their efforts at discovering a means to induce the brains neuroplasiticy to enhance rehabilitative care.
| CSNX: HSM 23

24. www.heliusmedical.com | CSNX: HSM
THE TEAM
Montel Williams, Spokesperson, Personal User & Shareholder
Montel Williams earned his media celebrity status as an inspirational Emmy Award winning television personality whom Americans invited into their homes for more than 17 years. He is a decorated former naval officer, inspirational speaker, author, entrepreneur and advocate for patients worldwide.
Mr Williams is a personal user of the PoNS technology and is passionate about bringing this technology to market for the benefits of patients suffering from neurological symptoms
In addition to Helius Medical Technologies, Mr. Williams has several business interest in HealthCare, Renewable Energy and Consumer Products.
| CSNX: HSM 24

25. Helius Medical Technologies, Inc. 
Suite 1980, 1075 West Georgia Street Vancouver, BC, Canada, V6E 3C9 T: E: W: